Edition:
United States

Paratek Pharmaceuticals Inc (PRTK.OQ)

PRTK.OQ on NASDAQ Stock Exchange Global Market

17.45USD
14 Dec 2017
Change (% chg)

$-0.45 (-2.51%)
Prev Close
$17.90
Open
$18.00
Day's High
$18.10
Day's Low
$17.25
Volume
97,690
Avg. Vol
111,612
52-wk High
$29.00
52-wk Low
$13.20

Select another date:

Fri, Dec 1 2017

BRIEF-Paratek Pharmaceuticals Files For Mixed Shelf Offering Of Up To $250 Mln

* PARATEK PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250 MILLION - SEC FILING‍​ Source text (http://bit.ly/2BqNSiB) Further company coverage:

BRIEF-Paratek Pharmaceuticals Q3 loss per share $0.77

* Paratek Pharmaceuticals reports third quarter 2017 financial results, remains on track to complete NDA submissions in first quarter of 2018

BRIEF-Paratek Pharmaceuticals to report Q3 results on Nov 8

* Paratek Pharmaceuticals to report third quarter 2017 financial results and provide update on clinical progress on November 8, 2017 Source text for Eikon: Further company coverage:

BRIEF-Consistent efficacy and safety profile observed in new analyses of OASIS-1 phase 3 study of omadacycline

* Consistent efficacy and safety profile observed in new analyses of OASIS-1 phase 3 study of omadacycline in patients with difficult to treat comorbid conditions

BRIEF-Paratek Pharma antibiotic granted additional qualified infectious disease product designation by FDA​

* Paratek Pharmaceuticals Inc - its antibiotic omadacycline has been granted additional qualified infectious disease product designation by U.S. FDA​ Source text for Eikon: Further company coverage:

BRIEF-Paratek Pharmaceuticals Inc Q2 loss per share $0.66

* Paratek Pharmaceuticals, Inc. Reports second quarter 2017 financial results and provides clinical update

BRIEF-Paratek Pharmaceuticals Q2 loss per share $0.66

* Q2 earnings per share view $-0.96 -- Thomson Reuters I/B/E/S Source text for Eikon: (http://bit.ly/2f7JhMk) Further company coverage:

BRIEF-Paratek says Omadacycline showed high clinical success rates for infections by Absssi pathogens

* Says phase 3 study of oral-only dosing of Omadacycline met all primary, secondary endpoints in acute bacterial skin infections

BRIEF-Paratek Pharma Inc says co and Paratek Pharma LLC entered into amendment No. 3 to loan and security agreement

* Paratek pharmaceuticals inc - on june 27, co and paratek pharma, llc entered into amendment no. 3 to loan and security agreement dated sept. 30, 2015

Select another date: